Open-Label, Multicentre, Multiple Dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Cariprazine in Adolescent Subjects with Schizophrenia, Schizoaffective- and Schizophreniform Disorders Compared to Adults
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2018
At a glance
- Drugs Cariprazine (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Gedeon Richter
- 24 Jul 2018 Status changed from recruiting to completed.
- 10 Feb 2018 Planned number of patients changed from 54 to 83.
- 30 Jan 2017 New trial record